The MLL Muenchner Leukaemielabor GmbH is described in the management report as a worldwide leading institution in leukemia diagnostics and research measured by test volume and scientific publications. The company operates a national and international laboratory via MLL MVZ GmbH and provides a broad diagnostic portfolio including cytomorphology, chromosome analysis, FISH, immunophenotyping and numerous molecular genetic procedures. MLL has an accredited workflow implementing genome sequencing, cloud computing and artificial intelligence applications that are already used in routine diagnostics or imminent deployment. MLL has been accredited according to DIN EN ISO/IEC 17025 since 2009, was certified to DIN EN ISO 14001 in 2021 and the affiliated MLL Dx GmbH has been accredited by the College of American Pathologists since 2021. MLL Münchner Leukämielabor GmbH is a family business with open business succession. The company is a small company under § 267 (1) HGB and is therefore not required to publish a profit-and-loss statement.
Forschung und Dienstleistung im Bereich Leukämiediagnostik. Die Gesellschaft kooperiert mit der MHP Münchner Hämatologie Praxis, Prof. Dr. Dr. Torsten Haferlach, Facharzt für innere Medizin, Prof. Dr. Wolfgang Kern, Facharzt für innere Medizin, Prof. Dr. Claudia Haferlach, Ärzti, Partnerschaft ("MHP"-AG München, PR 879). Die Gesellschaft übt keine Heilkunde aus.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) München Local Court, HRB 155656 (as of 31 October 2026)
| Name | Type | City |
|---|---|---|
| Claudia Haferlach | Geschäftsführer(in) | München |
| Torsten Haferlach | Geschäftsführer(in) | München |
| Wolfgang Kern | Geschäftsführer(in) | Starnberg |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 155656 (as of 31 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 16.09.2021 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 30.11.2020 | Business Purpose Update | Forschung und Dienstleistung im Bereich Leukämiediagnostik. Die Gesellschaft kooperiert mit der MHP Münchner Hämatologie Praxis, Prof. Dr. Dr. Torsten Haferlach, Facharzt für innere Medizin, Prof. Dr. Wolfgang Kern, Facharzt für innere Medizin, Prof. Dr. Claudia Haferlach, Ärzti, Partnerschaft ("MHP"-AG München, PR 879). Die Gesellschaft übt keine Heilkunde aus. |
| 30.11.2020 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 17.01.2005 | Share Capital Set | — | 100.000 € |
Source: German Commercial Register (Handelsregister) München Local Court, HRB 155656 (as of 31 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | ≤ €15M1 | — | €16,345,417 | — |
| 2023 | Rohergebnis€8.6M2 | €986,844 | €12,588,262 | — |
| 2022 | Rohergebnis€7.3M2 | €1,004,900 | €12,695,500 | — |
| 2021 | Rohergebnis€10.4M2 | €1,445,406 | €10,652,894 | — |
| 2020 | Rohergebnis€13.9M2 | €1,764,496 | €13,927,796 | — |
| 2019 | Rohergebnis€11.4M2 | €1,011,565 | €14,357,887 | — |
| 2018 | ≤ €12M1 | -€1,787,332 | €16,490,289 | — |
| 2017 | ≤ €12M1 | €533,476 | €17,696,756 | — |
| 2016 | ≤ €12M1 | €427,422 | €12,213,130 | — |
| 2015 | ≤ €12M1 | €431,716 | €11,398,166 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) München Local Court, HRB 155656 (as of 31 October 2026)
Klinikum Merzig gGmbH
Merzig · Krankenhäuser (ohne Hochschulkliniken, Vorsorge- und Rehabilitationskliniken)
GBA Central Lab Services GmbH
Schwentinental · Erbringung von Dienstleistungen von medizinischen Laboratorien
gematik GmbH
Berlin · Erbringung von Dienstleistungen der diagnostischen Bildgebung
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €336,960 | 9.7% |
| Depreciation | €2,983,223 | 85.5% |
| Interest & Similar | €167,046 | 4.8% |
